Cabaletta Bio, Inc. (CABA) research
Cabaletta Bio, Inc.- Sector
- Biotechnology
- Last price
- $2.00
- As of
Cabaletta Bio, Inc. (CABA): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.
As of . Source: SEC EDGAR filings for CABA. Method and limitations.
Share the CABA intelligence card
See the full CABA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CABA on one page. Preview it with sample data, then open it live with a free account.
Preview the CABA dossierActive signals for CABA
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 65% of CABA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1482% to CABA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +121% to CABA (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 52% of CABA (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 10.7%, EPS $-0.34 vs $-0.3807 estimate
FREE, NO ACCOUNT
Every signal on CABA, as it fires
You are seeing 5 of 13 signals recorded on CABA since 2026-06-10.
The five above landed across 2 days. The other 8 were recorded on 3 other days. 7 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CABA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 12674W109 · 2026Q2 | $11M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 12674W109 · 2026Q2 | $6.4M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 12674W109 · 2026Q2 | $4.8M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 12674W109 · 2026Q2 | $4.4M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 12674W109 · 2026Q2 | $282K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CABA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CABA against its peers
CABA's return on equity of -149.8% ranks in the 7th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | CABA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 12.6M | n/a | 18 |
| Operating margin | n/a | -699.8% | n/a | 16 |
| Net margin | n/a | -377.7% | n/a | 16 |
| Return on equity | -149.8% | -41.4% | 7 | 20 |
Peers (23): LRMR, BBOT, EBS, ARTV, EVMN, BNTC, PRLD, OCGN, LXEO, SRZN, VNDA, IPSC, PROK, ABEO, RCKT, OBIO, FENC, EYPT, XFOR, IKT, FATE, UPB, QTTB. Left out: VOGX (no annual filing), CUVL (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (CABA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CABA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CABAand get the insider, 13F, options, and confluence read in one view.